Gilead Sciences, Inc. company logo

# 1st Gen Model Gilead Sciences, Inc. Biological products, except diagnostic

Subscribe >> Deal exit on
Oct. 23, 2017
Deal entry on
Oct. 23, 2017
0.52%Expected margin
60.24% successful of 83 deals
$81.21 Last close price
at 20-oct-2017


Model's trade recommendations 7.08% Return for period

-0.34% Annual return

$104.49B Market Cap

β 1.14  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 7.08%
52wk return 12.22%
52wk Range
Sortino ratio 0.02
Sharpe ratio 0.01
Norm. RMSE 0.21%
Downside risk 10.25%
Volatility 12.70%
  • 2.08 (2.60%) Div (Yield)
  • BUY Analysts consensus recommendation

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugsthat are safer, easier for patients to tolerate and more effective.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Gilead Sciences, Inc. (GILD) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 23, 2015.

Market data for GILD model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 1289M
P/E 7.96
Shares Outstanding 1306M
% Held by Insiders 1.30%
% Held by Institutions 73.97%
EPS (last reported FY) $11.37
EPS (last reported Q) $2.51
EPS, estimated (last reported Q) $2.11
Total revenues $30 B
Net income $14 B